News
Public · Published
Citigroup maintains West Pharmaceutical Servs at Buy, raises price target to $494 from $412
Citigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, a 19.9% increase. That target implies 19.7% upside from the October 30 close of $412.62.
Published:
Updated:
What happened
Citigroup kept its Buy rating on West Pharmaceutical Services and raised its price target to $494 from $412, a 19.9% increase. That target implies 19.7% upside from the October 30 close of $412.62.
Confirmed
Global impact / market context
A higher price target signals that this analyst expects the stock to be worth more than before. Investors who follow ratings may treat it as a sign of confidence in the company's future profit and sales growth.
Analyst inference
Other recent analyst notes set targets between $480 and $500, so Citigroup's $494 sits inside that range. This suggests several analysts share a similar view on the stock, rather than one firm standing alone.
Analyst inference
What to watch
- Citigroup maintained a Buy rating, which means it still expects the stock to perform well for investors over time. Confirmed
- Watch whether other analysts change their price targets, since a cluster of higher targets can shift how investors position money in the stock. Analyst inference
- Watch the company's next financial results, because actual sales and profit could confirm or challenge these analyst expectations. Analyst inference
Evidence
- Original source link unavailable